These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 28877664)

  • 1. Adherence, satisfaction and functional health status among patients with multiple sclerosis using the BETACONNECT® autoinjector: a prospective observational cohort study.
    Kleiter I; Lang M; Jeske J; Norenberg C; Stollfuß B; Schürks M
    BMC Neurol; 2017 Sep; 17(1):174. PubMed ID: 28877664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of Adherence Among Patients With Multiple Sclerosis Using the BETACONNECT
    Köhler W; Bayer-Gersmann K; Neußer T; Schürks M; Ziemssen T
    Front Neurol; 2021; 12():643126. PubMed ID: 33716945
    [No Abstract]   [Full Text] [Related]  

  • 3. BetaEval Global: Prospective, Multinational, Observational Cohort Study of Patients Using BETACONNECT
    Patti F; Martínez Ginés ML; Norenberg C; Duarte Caron F
    Patient Prefer Adherence; 2020; 14():771-779. PubMed ID: 32425509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Medication Adherence Using a Medical App Among Patients With Multiple Sclerosis Treated With Interferon Beta-1b: Pilot Digital Observational Study (PROmyBETAapp).
    Limmroth V; Hechenbichler K; Müller C; Schürks M
    J Med Internet Res; 2019 Jul; 21(7):e14373. PubMed ID: 31359863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survey of US Patients with Multiple Sclerosis: Comparison of the New Electronic Interferon Beta-1b Autoinjector (BETACONNECT™) With Mechanical Autoinjectors.
    Barone DA; Singer BA; Merkov L; Rametta M; Suarez G
    Neurol Ther; 2016 Dec; 5(2):155-167. PubMed ID: 27277705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient satisfaction with ExtaviPro™ 30G, a new auto-injector for administering interferon β-1b in multiple sclerosis: results from a real-world, observational EXCHANGE study.
    Hoffmann FA; Trenova A; Llaneza MA; Fischer J; Lus G; von Bredow D; Lara N; Lam E; Van Hoef M; Bakshi R
    BMC Neurol; 2017 Aug; 17(1):156. PubMed ID: 28793876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™).
    Ziemssen T; Sylvester L; Rametta M; Ross AP
    Neurol Ther; 2015 Dec; 4(2):125-36. PubMed ID: 26662362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Assessment of Interferon-β-1b and Interferon-β-1a Adherence Before and After the Introduction of the BETACONNECT
    Butler O; Heeg S; Holl K; Frenz AK; Wicklein EM; Rametta M; Yeo S
    Drugs Real World Outcomes; 2021 Sep; 8(3):359-367. PubMed ID: 33928518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Prospective, Observational, Multicenter Study Assessing Adherence to Interferon Beta-1b Therapy and Patient Satisfaction Using the BETACONNECT Auto-Injector.
    Farej R; Rametta M; La Rose A; Quillen A; McLeod K
    Neurol Ther; 2022 Mar; 11(1):373-384. PubMed ID: 35064907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study.
    Devonshire V; Arbizu T; Borre B; Lang M; Lugaresi A; Singer B; Verdun di Cantogno E; Cornelisse P
    BMC Neurol; 2010 Apr; 10():28. PubMed ID: 20433746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of betaplus program on patient treatment satisfaction with interferon beta-1b in multiple sclerosis: Multicentric cross-sectional survey in the western Balkan countries.
    Drulovic J; Cukic M; Grgic S; Dincic E; Raicevic R; Nadj C; Toncev G; Vojinovic S; Mesaros S; Kisic Tepavcevic D; Dujmovic I; Tadic D; Miletic-Drakulic S; Dackovic J; Kostic S; Erakovic J; Sakalas L; Savic D; Suknjaja V; Martinovic V; Maric G; Pekmezovic T
    Mult Scler Relat Disord; 2017 Jan; 11():56-61. PubMed ID: 28104258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of adherence to, and persistence with, an electromechanical autoinjector for subcutaneous interferon beta-1a injections for multiple sclerosis treatment over 3 years.
    Piras F; Arnaud L; Henninger E; Keiser M; Seitzinger A; Jack D; Le Masne Q
    Expert Opin Drug Deliv; 2023 Jun; 20(6):863-870. PubMed ID: 37273189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ease of use of two autoinjectors in patients with multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: results of the randomized, crossover REDEFINE study.
    Wray S; Hayward B; Dangond F; Singer B
    Expert Opin Drug Deliv; 2018 Feb; 15(2):127-135. PubMed ID: 29206056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence to Long-Term Interferon Beta-1b Injection Therapy in Patients with Multiple Sclerosis Using an Electronic Diary.
    Zettl UK; Bauer-Steinhusen U; Glaser T; Czekalla J; Hechenbichler K; Limmroth V; Hecker M
    Adv Ther; 2016 May; 33(5):834-47. PubMed ID: 27090116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ascertaining Medication Use and Patient-Reported Outcomes via an App and Exploring Gamification in Patients With Multiple Sclerosis Treated With Interferon β-1b: Observational Study.
    Limmroth V; Bayer-Gersmann K; Mueller C; Schürks M
    JMIR Form Res; 2022 Mar; 6(3):e31972. PubMed ID: 35285806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple sclerosis patients treated with intramuscular IFN-β-1a autoinjector in a real-world setting: prospective evaluation of treatment persistence, adherence, quality of life and satisfaction.
    Hupperts R; Becker V; Friedrich J; Gobbi C; Salgado AV; Sperling B; You X
    Expert Opin Drug Deliv; 2015 Jan; 12(1):15-25. PubMed ID: 25430947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sleep quality, daytime sleepiness, fatigue, and quality of life in patients with multiple sclerosis treated with interferon beta-1b: results from a prospective observational cohort study.
    Kotterba S; Neusser T; Norenberg C; Bussfeld P; Glaser T; Dörner M; Schürks M
    BMC Neurol; 2018 Aug; 18(1):123. PubMed ID: 30143019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence to Subcutaneous IFN β-1a in Multiple Sclerosis: Final Analysis of the Non-Interventional Study READOUTsmart Using the Dosing Log and Readout Function of RebiSmart
    Rieckmann P; Schwab M; Pöhlau D; Penner IK; Wagner T; Schel E; Bayas A
    Adv Ther; 2019 Jan; 36(1):175-186. PubMed ID: 30488338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study.
    Bayas A; Ouallet JC; Kallmann B; Hupperts R; Fulda U; Marhardt K;
    Expert Opin Drug Deliv; 2015 Aug; 12(8):1239-50. PubMed ID: 26098143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subjective patient-reported versus objective adherence to subcutaneous interferon β-1a in multiple sclerosis using RebiSmart®: the CORE study.
    Zecca C; Disanto G; Mühl S; Gobbi C
    BMC Neurol; 2017 Sep; 17(1):171. PubMed ID: 28870152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.